Armenta
Non-antibiotic Treatment of Mastitis in Dairy Cows
Agriculture & Food Technologies
Private
Company Overview
Snapshot
Founded in June 2018 by Itzhak Friedman and Eddy Papirov, Armenta operates with 11–50 employees. The company has raised $8.35M across 3 funding rounds from 3 investors.
Business overview
Armenta is an agriculture technology company that develops novel therapies for dairy cattle diseases, specifically focusing on the non-antibiotic treatment of mastitis. The company utilizes proprietary acoustic pulse therapy (APT) technology and related devices designed for treating dairy cows. Armenta operates within the Agriculture & Food Technologies and Health Tech & Life Sciences sectors, serving the livestock market, particularly dairy farms.
Log in to access full profile ›Company Intelligence Q&A
- What is Armenta's primary focus?
- Armenta's primary focus is on developing non-antibiotic treatments for mastitis in dairy cows, aiming to prevent monetary losses resulting from this common pathology.
- When was Armenta founded and by whom?
- Armenta was founded in June 2018 by Itzhak Friedman and Eddy Papirov.
- What technology does Armenta utilize?
- Armenta utilizes proprietary acoustic pulse therapy (APT) technology, which has been adapted for treating inflammatory diseases in dairy cows.
- How much capital has Armenta raised to date?
- Armenta has raised a total of $8.35M across 3 funding rounds.